NASDAQ:NERV Minerva Neurosciences (NERV) Stock Price, News & Analysis $5.26 -0.04 (-0.75%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$5.20 -0.06 (-1.24%) As of 05/22/2026 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Minerva Neurosciences Stock (NASDAQ:NERV) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Minerva Neurosciences alerts:Sign Up Key Stats Today's Range$5.20▼$5.5750-Day Range$4.36▼$8.0752-Week Range$1.35▼$12.46Volume84,007 shsAverage Volume149,931 shsMarket Capitalization$245.06 millionP/E RatioN/ADividend YieldN/APrice Target$10.50Consensus RatingHold Company Overview Minerva Neurosciences, Inc. is a clinical‐stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The company’s research and development efforts are directed toward addressing unmet needs in psychiatric and neurological conditions, leveraging its expertise in neuropharmacology and receptor modulation. Minerva’s goal is to bring forward differentiated molecules that can offer improved efficacy and safety profiles compared to existing treatments. The company’s most advanced programs include roluperidone (formerly MIN-101), which has been investigated for the treatment of negative symptoms of schizophrenia, and MIN-117, a novel serotonergic agent being evaluated in major depressive disorder. Roluperidone is designed to modulate a combination of sigma and adrenergic receptors without dopaminergic activity, potentially reducing side effects associated with traditional antipsychotics. MIN-117 targets multiple serotonin receptor subtypes and the serotonin transporter, with the aim of providing antidepressant benefit while minimizing common adverse events linked to selective serotonin reuptake inhibitors. Headquartered in Cambridge, Massachusetts, Minerva Neurosciences operates research facilities in the United States and collaborates with academic partners and contract research organizations worldwide to advance its pipeline through clinical development. The company was founded in 2013 and has since progressed multiple candidates through Phase 1 and Phase 2 trials. Under the leadership of President and Chief Executive Officer Vipin K. Garg, Minerva continues to explore strategic partnerships and funding opportunities to support late‐stage clinical trials and, ultimately, regulatory submissions.AI Generated. May Contain Errors. Read More Minerva Neurosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreNERV MarketRank™: Minerva Neurosciences scored higher than 52% of companies evaluated by MarketBeat, and ranked 486th out of 866 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingMinerva Neurosciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.Upside PotentialMinerva Neurosciences has a consensus price target of $10.50, representing about 99.6% upside from its current price of $5.26.Amount of Analyst CoverageMinerva Neurosciences has only been the subject of 3 research reports in the past 90 days.Read more about Minerva Neurosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Minerva Neurosciences are expected to grow in the coming year, from ($0.20) to $4.82 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Minerva Neurosciences is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Minerva Neurosciences is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.18% of the float of Minerva Neurosciences has been sold short.Short Interest Ratio / Days to CoverMinerva Neurosciences has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in Minerva Neurosciences has recently increased by 14.80%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMinerva Neurosciences does not currently pay a dividend.Dividend GrowthMinerva Neurosciences does not have a long track record of dividend growth. News and Social Media3.0 / 5News Sentiment0.74 News SentimentMinerva Neurosciences has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Minerva Neurosciences this week, compared to 2 articles on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Minerva Neurosciences insiders have not sold or bought any company stock.Percentage Held by Insiders10.40% of the stock of Minerva Neurosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions34.56% of the stock of Minerva Neurosciences is held by institutions.Read more about Minerva Neurosciences' insider trading history. Receive NERV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Minerva Neurosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NERV Stock News HeadlinesMinerva Neurosciences (NASDAQ:NERV) Shares Cross Below 200 Day Moving Average - Here's WhyMay 19, 2026 | americanbankingnews.comMinerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare ConferenceMay 18, 2026 | globenewswire.com$30 stock to buy before Starlink goes public (WATCH NOW!)A little-known stock pick with money-doubling potential over the next year is revealed for free in the first three minutes of a new video. This company is a critical piece of Elon Musk's fast-growing Starlink technology. It could climb 100 percent or more over the next year as Elon brings Starlink public in what may be the biggest IPO in history. No credit card is required to get the ticker.May 23 at 1:00 AM | Paradigm Press (Ad)Minerva Neurosciences, Inc: Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business UpdatesMay 5, 2026 | finanznachrichten.deMinerva Neurosciences Provides First Quarter 2026 Financial Results and Business UpdatesMay 5, 2026 | globenewswire.comMinerva Neurosciences (NERV) price target increased by 31.03% to 9.69April 28, 2026 | msn.comCitizens Initiates Coverage of Minerva Neurosciences (NERV) with Market Outperform RecommendationApril 16, 2026 | msn.comMinerva launched with New Outperform at Citizens on schizophrenia candidateApril 15, 2026 | seekingalpha.comSee More Headlines NERV Stock Analysis - Frequently Asked Questions How have NERV shares performed this year? Minerva Neurosciences' stock was trading at $4.02 on January 1st, 2026. Since then, NERV stock has increased by 30.8% and is now trading at $5.26. How were Minerva Neurosciences' earnings last quarter? Minerva Neurosciences, Inc (NASDAQ:NERV) announced its earnings results on Tuesday, May, 5th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by $0.04. When did Minerva Neurosciences' stock split? Minerva Neurosciences's stock reverse split on the morning of Tuesday, June 21st 2022.The 1-8 reverse split was announced on Tuesday, June 21st 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, June 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. When did Minerva Neurosciences IPO? Minerva Neurosciences (NERV) raised $33 million in an initial public offering on Thursday, June 26th 2014. The company issued 5,454,545 shares at $6.00 per share. Who are Minerva Neurosciences' major shareholders? Top institutional investors of Minerva Neurosciences include Janus Henderson Group PLC (9.22%), Renaissance Technologies LLC (0.19%), Bank of America Corp DE (0.09%) and Cannon Global Investment Management LLC (0.04%). View institutional ownership trends. How do I buy shares of Minerva Neurosciences? Shares of NERV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Minerva Neurosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Minerva Neurosciences investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Meta Platforms (META), NIO (NIO), TherapeuticsMD (TXMD), Inovio Pharmaceuticals (INO) and VBI Vaccines (VBIV). Company Calendar Last Earnings5/05/2026Today5/23/2026Jefferies Global Healthcare Conference 20266/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3d) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 As of 3 days ago, NERV's financial health entered the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NERV CIK1598646 Webwww.minervaneurosciences.com Phone(617) 600-7373FaxN/AEmployees9Year Founded2007Price Target and Rating Average Price Target for Minerva Neurosciences$10.50 High Price Target$14.00 Low Price Target$7.00 Potential Upside/Downside+99.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($29.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$293.42 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-32.63% Debt Debt-to-Equity RatioN/A Current Ratio17.65 Quick Ratio17.65 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($5.45) per share Price / Book-0.97Miscellaneous Outstanding Shares46,590,000Free Float41,744,000Market Cap$245.06 million OptionableNot Optionable Beta-0.08 Social Links Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:NERV) was last updated on 5/23/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredThe AI stocks about to become worthless (and one that isn't)Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being ...InvestorPlace | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Minerva Neurosciences, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Minerva Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
